Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma

BACKGROUND: Bortezomib is an approved proteasome inhibitor for the treatment of certain lymphoma subtypes. Two clinical trials investigated bortezomib in patients with malignant pleural mesothelioma (MPM) and failed to improve outcome. We present a potential explanation for this event. METHODS: 171...

Descripción completa

Detalles Bibliográficos
Autores principales: Walter, Robert Fred Henry, Sydow, Saskia Roxanne, Berg, Erika, Kollmeier, Jens, Christoph, Daniel Christian, Christoph, Sandra, Eberhardt, Wilfried Ernst Erich, Mairinger, Thomas, Wohlschlaeger, Jeremias, Schmid, Kurt Werner, Mairinger, Fabian Dominik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6765394/
https://www.ncbi.nlm.nih.gov/pubmed/31576173
http://dx.doi.org/10.2147/CMAR.S194337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6765394/
https://www.ncbi.nlm.nih.gov/pubmed/31576173
http://dx.doi.org/10.2147/CMAR.S194337

Ejemplares similares